Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


  1. 2022
  2. Published

    Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor

    Rafaeva, Maria, Horton, E. R., Jensen, A. R. D., Madsen, C. D., Reuten, R., Willacy, O., Brøchner, Christian Beltoft, Jensen, Thomas Hartvig Lindkær, Zornhagen, Kamilla Westarp, Crespo Bravo, Marina, Grønseth, D. S., Nielsen, S. R., Idorn, M., Straten, P. T., Rohrberg, K., Spanggaard, I., Højgaard, M., Lassen, Ulrik Niels, Erler, Janine & Mayorca Guiliani, Alejandro Enrique, 2022, In: Advanced Healthcare Materials. 11, 1, 2100684.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Patients in phase 1 cancer trials: psychological distress and understanding of trial information

    Gad, K. T., Lassen, Ulrik Niels, Duun-Henriksen, A. K., Dalton, Susanne Oksbjerg, Mau-Sørensen, M., Bidstrup, P. E., Høeg, B. L., Rohrberg, K. S., Spanggard, I., von Heymann, A. & Johansen, Christoffer, 2022, In: Acta Oncologica. 61, 3, p. 341-348 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

    Yang, J. C. H., Brose, M. S., Castro, G., Kim, E. S., Lassen, Ulrik Niels, Leyvraz, S., Pappo, A., López-Ríos, F., Reeves, J. A., Fellous, M., Penault-Llorca, F., Rudzinski, E. R., Tabatabai, G., Vassal, G., Drilon, A. & Trent, J., 2022, In: BMC Cancer. 22, 1, 625.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy

    Eriksen, M., Yde, C. W., Ahlborn, L. B., Qvortrup, Camilla, Lassen, Ulrik Niels, Højgaard, M., Spanggaard, I. & Rohrberg, K. S., 2022, In: European Journal of Cancer. 174, S1, p. S118

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  6. Published

    Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

    Lazar, V., Girard, N., Raymond, E., Martini, J., Galbraith, S., Raynaud, J., Bresson, C., Solomon, B., Magidi, S., Nechushtan, H., Onn, A., Berger, R., Chen, H., Al-omari, A., Ikeda, S., Lassen, U., Sekacheva, M., Felip, E., Tabernero, J., Batist, G. & 10 others, Spatz, A., Pramesh, C. S., Girard, P., Blay, J., Philip, T., Berindan-neagoe, I., Porgador, A., Rubin, E., Kurzrock, R. & Schilsky, R. L., 2022, In: JCO Precision Oncology. 6, 12 p., e2200072.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study

    Nørøxe, D. S., Flynn, A., Yde, C. W., Østrup, O., Nielsen, Finn Cilius, Skjøth, Jane, Brennum, J., Hamerlik, P., Weischenfeldt, Joachim Lütken, Skovgaard Poulsen, H. & Lassen, Ulrik Niels, 2022, In: Molecular Oncology. 16, 1, p. 206-218

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. 2021
  9. Published

    Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

    Araujo B. de Lima, V., Hansen, M., Spanggaard, I., Rohrberg, K., Reker Hadrup, S., Lassen, Ulrik Niels & Svane, Inge Marie, 25 Mar 2021, In: Frontiers in Oncology. 11, 11 p., 558248.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology

    Rohrberg, K. S. & Lassen, Ulrik Niels, 2021, In: Drugs. 81, 4, p. 445-452 8 p.

    Research output: Contribution to journalReviewResearchpeer-review

  11. Published

    Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors

    Wick, A., Bahr, O., Schuler, M., Rohrberg, K., Chawla, S. P., Janku, F., Schiff, D., Heinemann, V., Narita, Y., Lenz, H. J., Ikeda, M., Ando, Y., Wick, W., Steinbach, J. P., Burger, M. C., Wenger, K., Lassen, U., Sankhala, K. K., Roggia, C., Genvresse, I. & 11 others, Munhoz, C., Rentzsch, C., Reschke, S., Langer, S., Wagner, M., Kaulfuss, S., Cai, C., Lagkadinou, E., Jeffers, M., Peña, C. & Tabatabai, G., 2021, In: Clinical Cancer Research. 27, 10, p. 2723-2733 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  12. 2020
  13. Published

    Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply

    Subbiah, V., Lassen, Ulrik Niels, Gasal, E., Burgess, P. & Wainberg, Z. A., 1 Nov 2020, In: The Lancet Oncology. 21, 11, p. e516 1 p.

    Research output: Contribution to journalComment/debateResearch

Previous 1 2 3 4 5 6 7 8 ...16 Next

ID: 4952653